$50,000 of TANDEM DIABETES CARE lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Medicare coverage of insulin pumps. Issues related to Medicare durable medical equipment competitive bidding. Issues related to Medicare coverage of insulin pumps."
You can find more data on corporate lobbying on Quiver Quantitative.
TNDM Insider Trading Activity
TNDM insiders have traded $TNDM stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TNDM stock by insiders over the last 6 months:
- LEIGH VOSSELLER (EVP & CHIEF FINANCIAL OFFICER) purchased 13,720 shares for an estimated $149,403
- JOHN F SHERIDAN (PRESIDENT & CEO) purchased 10,000 shares for an estimated $102,318
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
TNDM Hedge Fund Activity
We have seen 150 institutional investors add shares of TNDM stock to their portfolio, and 113 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OPHIR ASSET MANAGEMENT PTY LTD added 1,464,956 shares (+inf%) to their portfolio in Q2 2025, for an estimated $27,306,779
- GOLDMAN SACHS GROUP INC added 1,173,916 shares (+164.7%) to their portfolio in Q2 2025, for an estimated $21,881,794
- PARK WEST ASSET MANAGEMENT LLC removed 1,123,052 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $20,933,689
- FMR LLC removed 912,401 shares (-63.5%) from their portfolio in Q2 2025, for an estimated $17,007,154
- FRED ALGER MANAGEMENT, LLC removed 786,894 shares (-54.1%) from their portfolio in Q2 2025, for an estimated $14,667,704
- MILLENNIUM MANAGEMENT LLC added 741,488 shares (+325.8%) to their portfolio in Q2 2025, for an estimated $13,821,336
- TWO SIGMA INVESTMENTS, LP added 591,285 shares (+92.2%) to their portfolio in Q2 2025, for an estimated $11,021,552
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TNDM Analyst Ratings
Wall Street analysts have issued reports on $TNDM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/29/2025
- Oppenheimer issued a "Outperform" rating on 09/08/2025
- Barclays issued a "Overweight" rating on 08/08/2025
- RBC Capital issued a "Outperform" rating on 08/07/2025
- Stifel issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for TNDM, check out Quiver Quantitative's $TNDM forecast page.
TNDM Price Targets
Multiple analysts have issued price targets for $TNDM recently. We have seen 12 analysts offer price targets for $TNDM in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Joanne Wuensch from Citigroup set a target price of $15.0 on 10/07/2025
- William Plovanic from Canaccord Genuity set a target price of $24.0 on 09/29/2025
- Steven Lichtman from Oppenheimer set a target price of $22.0 on 09/08/2025
- Brooks O'Neil from Lake Street set a target price of $12.0 on 08/11/2025
- Matt Miksic from Barclays set a target price of $51.0 on 08/08/2025
- Shagun Singh from RBC Capital set a target price of $25.0 on 08/07/2025
- Larry Biegelsen from Wells Fargo set a target price of $13.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
